Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatogenic diabetes].

G Perseghin, M Caloni, V Mazzaferro

    Recenti Progressi in Medicina
    |February 2, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Diabetes in liver cirrhosis stems from insulin resistance and impaired liver function. Factors like genetics, iron, and infections worsen beta-cell function, leading to diabetes onset.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study.

    ESMO gastrointestinal oncology·2026
    Same author

    Effect of pollution on the prevalence of obesity, diabetic complications and olfactory dysfunction in diabetic patients.

    Journal of endocrinological investigation·2025
    Same author

    Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

    ESMO open·2025
    Same author

    Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.

    ESMO open·2025
    Same author

    Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Olfactory dysfunction in patients with type 2 diabetes mellitus.

    Rhinology·2024
    Same journal

    Recenti progressi in medicina·2026
    Same journal

    Recenti progressi in medicina·2026
    Same journal

    Recenti progressi in medicina·2026
    Same journal

    Recenti progressi in medicina·2026
    Same journal

    Recenti progressi in medicina·2026
    Same journal

    Recenti progressi in medicina·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Endocrinology
    • Metabolic Disorders

    Background:

    • Liver cirrhosis frequently leads to diabetes mellitus, primarily due to peripheral insulin resistance and impaired hepatocellular function.
    • The exact mechanisms of insulin resistance (receptorial or post-receptorial) in cirrhosis are not fully understood but significantly impact liver disease progression.
    • Beta-cell function is critical for compensating insulin resistance and preventing overt diabetes in these patients.

    Discussion:

    • Several factors contribute to reduced beta-cell function in liver cirrhosis patients.
    • These include pre-existing diabetes predispositions (genetic, environmental) and liver disease-specific factors.
    • Hepatic disease-related factors such as iron deposition in the liver and islets of Langerhans, Hepatitis C Virus (HCV) infection, and hepatocellular carcinoma (HCC) can critically exacerbate beta-cell dysfunction.

    Related Experiment Videos

    Key Insights:

    • The high prevalence of diabetes in liver cirrhosis is attributed to a combination of early-onset, severe insulin resistance and compromised beta-cell function.
    • Liver disease-specific factors significantly contribute to and aggravate the deficient beta-cell capacity.
    • Understanding these multifactorial elements is crucial for managing diabetes in liver cirrhosis.

    Outlook:

    • Further research into the specific pathways of insulin resistance in cirrhosis is warranted.
    • Investigating therapeutic strategies targeting beta-cell function and mitigating disease-specific factors could improve diabetes management in liver cirrhosis.
    • Longitudinal studies are needed to fully elucidate the natural history and impact of diabetes on liver disease progression.